The Lactibiane Référence 2,5g clinical study

PiLeJe Laboratory carried out the first clinical study in France intended to measure the impact of Lactibiane Référence 2,5g probiotics on Intestinal Functional Disorders. Led by Pr. Marteau, the results are convincing...

A rigorous and controlled methodology

The Lactibiane 2,5g clinical study was carried out at the Georges-Pompidou European Hospital, between September 2004 and January 2006, with 100 participating volunteers,
selected on the basis of their problems with intestinal functional disorders.
 

The clinical study was carried out as double-blind with a placebo control : among patients selected, 48 took a sachet of Lactibiane Référence 2,5g daily while 52 persons took a placebo sachet, with neither of the two groups knowing the precise contents of the sachets consumed.

The duration of supplementation was set at 28 consecutive days. Each week, the patients had to assess their pain / discomfort levels by filling out questionnaires. They also completed a questionnaire on quality of life at the start and completion of treatment.

The results : the efficacity of Lactibiane Référence 2,5 g was demonstrated

Lactibiane Référence 2.5 g contains 10 billion probiotic lactic ferments (Bifidobacterium longum LA101, Lactobacillus acidophilus LA102, Lactococcus lactis LA103, and Streptococcus thermophilus LA104).

Consuming one sachet of Lactibiane Référence 2,5g a day for 4 weeks can :

- reduce abdominal pain associated with irritable bowel syndrome by 43%
- improve the quality of life, especially by reducing digestive discomfort
(bloating, flatulence).

This supplementation is also accompanied by improvement in bowel function in subjects with predominating symptoms of constipation

Click here to watch the results of Lactibiane Référence 2,5g study by Pr Marteau